Combining Intratumoral Treg Depletion with Androgen Deprivation Therapy (ADT): Preclinical Activity in the Myc-CaP Model

Overview

Journal Prostate Cancer Prostatic Dis

Specialties Oncology
Urology

Date 2017 Dec 6

PMID 29203894

Citations 33

Authors

Ying-Chun Shen

Ali Ghasemzadeh

Christina M Kochel

Thomas R Nirschl

Brian J Francica

Zoila A Lopez-Bujanda

Maria A Carrera Haro

Ada Tam

Robert A Anders

Mark J Selby

Alan J Korman

Charles G Drake

Affiliations

Soon will be listed here.

Abstract

Background: Immune checkpoint blockade has shown promising antitumor activity against a variety of tumor types. However, responses in castration-resistant prostate cancer remain relatively rare-potentially due to low baseline levels of infiltration. Using an immunocompetent cMyc-driven model (Myc-CaP), we sought to understand the immune infiltrate induced by androgen deprivation therapy (ADT) and to leverage that infiltration toward therapeutic benefit.

Methods: Using flow cytometry, qPCR and IHC, we quantified ADT-induced immune infiltration in terms of cell type and function. Preclinical treatment studies tested the combinatorial effects of ADT and immune checkpoint blockade using tumor outgrowth and overall survival as end points.

Results: ADT induces a complex pro-inflammatory infiltrate. This pro-inflammatory infiltrate was apparent in the early postcastration period but diminished as castration resistance emerged. Combining ADT with tumor-infiltrating regulatory T cell (Treg) depletion using a depleting anti-CTLA-4 antibody significantly delayed the development of castration resistance and prolonged survival of a fraction of tumor-bearing mice. Immunotherapy as a monotherapy failed to provide a survival benefit and was ineffective if not administered in the peri-castration period.

Conclusions: The immune infiltrate induced by ADT is diverse and varies over time. Therapeutic strategies focusing on depleting Tregs in the peri-castration period are of particular interest.

Citing Articles

Evolution of myeloid-mediated immunotherapy resistance in prostate cancer.

Lyu A, Fan Z, Clark M, Lea A, Luong D, Setayesh A Nature. 2024; 637(8048):1207-1217.

PMID: 39633050 PMC: 11779626. DOI: 10.1038/s41586-024-08290-3.

Neoadjuvant androgen deprivation therapy with or without Fc-enhanced non-fucosylated anti-CTLA-4 (BMS-986218) in high risk localized prostate cancer: a randomized phase 1 trial.

Ager C, Obradovic A, McCann P, Chaimowitz M, Wang A, Shaikh N medRxiv. 2024; .

PMID: 39314954 PMC: 11419205. DOI: 10.1101/2024.09.09.24313308.

Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer.

Dallos M, Obradovic A, McCann P, Chowdhury N, Pratapa A, Aggen D Clin Cancer Res. 2024; 30(22):5218-5230.

PMID: 39269310 PMC: 11905119. DOI: 10.1158/1078-0432.CCR-24-0060.

Targeting a STING agonist to perivascular macrophages in prostate tumors delays resistance to androgen deprivation therapy.

Al-Janabi H, Moyes K, Allen R, Fisher M, Crespo M, Gurel B J Immunother Cancer. 2024; 12(7).

PMID: 39060021 PMC: 11284826. DOI: 10.1136/jitc-2024-009368.

Activation of Stimulator of Interferon Genes (STING): Promising Strategy to Overcome Immune Resistance in Prostate Cancer.

Alnukhali M, Altabbakh O, Farooqi A, Pollack A, Daunert S, Deo S Curr Med Chem. 2024; 31(40):6556-6571.

PMID: 38347787 PMC: 11497144. DOI: 10.2174/0109298673273303231208071403.

References

Mercader M, Bodner B, Moser M, Kwon P, Park E, Manecke R . T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci U S A. 2001; 98(25):14565-70. PMC: 64722. DOI: 10.1073/pnas.251140998. View

Denmeade S, Isaacs J . A history of prostate cancer treatment. Nat Rev Cancer. 2002; 2(5):389-96. PMC: 4124639. DOI: 10.1038/nrc801. View

Nimmerjahn F, Bruhns P, Horiuchi K, Ravetch J . FcgammaRIV: a novel FcR with distinct IgG subclass specificity. Immunity. 2005; 23(1):41-51. DOI: 10.1016/j.immuni.2005.05.010. View

Watson P, Ellwood-Yen K, King J, Wongvipat J, LeBeau M, Sawyers C . Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line. Cancer Res. 2005; 65(24):11565-71. DOI: 10.1158/0008-5472.CAN-05-3441. View

Drake C, Jaffee E, Pardoll D . Mechanisms of immune evasion by tumors. Adv Immunol. 2006; 90:51-81. DOI: 10.1016/S0065-2776(06)90002-9. View

Sfanos K, Bruno T, Maris C, Xu L, Thoburn C, DeMarzo A . Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin Cancer Res. 2008; 14(11):3254-61. PMC: 3082357. DOI: 10.1158/1078-0432.CCR-07-5164. View

Chen Y, Sawyers C, Scher H . Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol. 2008; 8(4):440-8. PMC: 2574839. DOI: 10.1016/j.coph.2008.07.005. View

Li B, VanRoey M, Wang C, Chen T, Korman A, Jooss K . Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors. Clin Cancer Res. 2009; 15(5):1623-34. DOI: 10.1158/1078-0432.CCR-08-1825. View

Wada S, Yoshimura K, Hipkiss E, Harris T, Yen H, Goldberg M . Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model. Cancer Res. 2009; 69(10):4309-18. PMC: 3084614. DOI: 10.1158/0008-5472.CAN-08-4102. View

10.

Gannon P, Poisson A, Delvoye N, Lapointe R, Mes-Masson A, Saad F . Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients. J Immunol Methods. 2009; 348(1-2):9-17. DOI: 10.1016/j.jim.2009.06.004. View

11.

Ammirante M, Luo J, Grivennikov S, Nedospasov S, Karin M . B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature. 2010; 464(7286):302-5. PMC: 2866639. DOI: 10.1038/nature08782. View

12.

Nimmerjahn F, Lux A, Albert H, Woigk M, Lehmann C, Dudziak D . FcγRIV deletion reveals its central role for IgG2a and IgG2b activity in vivo. Proc Natl Acad Sci U S A. 2010; 107(45):19396-401. PMC: 2984189. DOI: 10.1073/pnas.1014515107. View

13.

Topalian S, Hodi F, Brahmer J, Gettinger S, Smith D, Mcdermott D . Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366(26):2443-54. PMC: 3544539. DOI: 10.1056/NEJMoa1200690. View

14.

Flammiger A, Weisbach L, Huland H, Tennstedt P, Simon R, Minner S . High tissue density of FOXP3+ T cells is associated with clinical outcome in prostate cancer. Eur J Cancer. 2012; 49(6):1273-9. DOI: 10.1016/j.ejca.2012.11.035. View

15.

Slovin S, Higano C, Hamid O, Tejwani S, Harzstark A, Alumkal J . Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Ann Oncol. 2013; 24(7):1813-1821. PMC: 3707423. DOI: 10.1093/annonc/mdt107. View

16.

Selby M, Engelhardt J, Quigley M, Henning K, Chen T, Srinivasan M . Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res. 2014; 1(1):32-42. DOI: 10.1158/2326-6066.CIR-13-0013. View

17.

Kwon E, Drake C, Scher H, Fizazi K, Bossi A, van den Eertwegh A . Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2014; 15(7):700-12. PMC: 4418935. DOI: 10.1016/S1470-2045(14)70189-5. View

18.

Bishop J, Sio A, Angeles A, Roberts M, Azad A, Chi K . PD-L1 is highly expressed in Enzalutamide resistant prostate cancer. Oncotarget. 2014; 6(1):234-42. PMC: 4381591. DOI: 10.18632/oncotarget.2703. View

19.

Topalian S, Drake C, Pardoll D . Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015; 27(4):450-61. PMC: 4400238. DOI: 10.1016/j.ccell.2015.03.001. View

20.

Callahan M, Postow M, Wolchok J . Targeting T Cell Co-receptors for Cancer Therapy. Immunity. 2016; 44(5):1069-78. DOI: 10.1016/j.immuni.2016.04.023. View